Pipeline · Cardiometabolic

Weight Loss.Pre-Clinical / Designed

Metabolic-rate, appetite-axis, and adipose-tissue inflammation triplet. Designed as a comparator and adjunct to GLP-1 standard of care — not a competitor but a stack-improver.

Status: Pre-Clinical / Designed
Therapeutic area: Cardiometabolic
Key: GLP-1 adjunct · Triplet axis

The mechanism we're betting on.

Metabolic-rate, appetite-axis, and adipose-tissue inflammation triplet. Designed as a comparator and adjunct to GLP-1 standard of care — not a competitor but a stack-improver. The full mechanism map — including compound list, dose escalation, pre-specified biomarker thresholds, and the cross-walk modifiers used when re-fitting blends from related indications — is part of the gated methodology pack.Gated

What the rest of the world is doing.

Numbers below are surfaced by Atlas Bio's ClinicalTrials.gov and PubMed RWE pipelines, run against the Weight Loss indication. Counts are industry-wide trials registered on ClinicalTrials.gov, not Atlas Bio studies. Methodology →

RWE refreshed 2026-05-12
Phase I (B1/B2)
292
trials
Phase II (B3)
366
trials
Phase III (B4)
359
trials
Phase IV (B5)
326
trials
Recent published clinical evidence

Locked before readout.

Predictions for this study are SHA-256 locked before any readout. Pre-registration covers target engagement, primary endpoint, secondary endpoints, and the falsification criterion. The hash, prediction wording, and timestamp are available to verified clinicians and indication researchers on request.Gated

Same stack, every indication.

Want the full Weight Loss protocol?

The abstract above is open. Compound lists, dose escalations, SHA-256-locked prediction documents, agent-network reasoning chains, and trial design specifics are available to verified clinicians, indication researchers, and sponsors under MNDA. Contact management to begin the access request.

Contact management →